Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer (TEX)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Thomas Hatschek, Karolinska University Hospital
ClinicalTrials.gov Identifier:
NCT01433614
First received: September 1, 2011
Last updated: September 16, 2015
Last verified: September 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2013
  Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)
Publications: